Targeting of anti-tumor responses with bispecific antibodies

D. M. Segal; J. H. Qian; D. Mezzanzanica; M. A. Garrido; J. A. Titus; S. M. Andrew; A. J T George; C. R. Jost; P. Perez; J. R. Wunderlich

Targeting of anti-tumor responses with bispecific antibodies

D. M. Segal, J. H. Qian, D. Mezzanzanica, M. A. Garrido, J. A. Titus, S. M. Andrew, A. J T George, C. R. Jost, P. Perez, J. R. Wunderlich

Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journal › Article › peer-review

Abstract

T cells can be induced to specifically lyse tumor cells with bispecific antibodies containing anti-T cell receptor mAbs crosslinked to anti-tumor mAbs. Such targeted cytolysis requires that the target cell be bound directly to the cytotoxic cell. In addition, targeted T cells mediate a second activity, the secretion of factors that can block the growth of both tumor target cells and bystander tumor cells. When given to nude mice bearing intraperitoneal human ovarian carcinoma, targeted human T cells cause the rapid removal of most tumor cells from the peritoneum, and markedly prolong the times of survival of treated mice. The efficacy of targeted T cells for treating human cancer is currently being tested in clinical trials.

Original language	English
Pages (from-to)	390-402
Number of pages	13
Journal	Immunobiology
Volume	185
Issue number	2-4
Publication status	Published - 1992

ASJC Scopus subject areas

Immunology

Cite this

@article{03330afa33214046945d4763d26a03b1,

title = "Targeting of anti-tumor responses with bispecific antibodies",

abstract = "T cells can be induced to specifically lyse tumor cells with bispecific antibodies containing anti-T cell receptor mAbs crosslinked to anti-tumor mAbs. Such targeted cytolysis requires that the target cell be bound directly to the cytotoxic cell. In addition, targeted T cells mediate a second activity, the secretion of factors that can block the growth of both tumor target cells and bystander tumor cells. When given to nude mice bearing intraperitoneal human ovarian carcinoma, targeted human T cells cause the rapid removal of most tumor cells from the peritoneum, and markedly prolong the times of survival of treated mice. The efficacy of targeted T cells for treating human cancer is currently being tested in clinical trials.",

author = "Segal, {D. M.} and Qian, {J. H.} and D. Mezzanzanica and Garrido, {M. A.} and Titus, {J. A.} and Andrew, {S. M.} and George, {A. J T} and Jost, {C. R.} and P. Perez and Wunderlich, {J. R.}",

year = "1992",

language = "English",

volume = "185",

pages = "390--402",

journal = "Immunobiology",

issn = "0171-2985",

publisher = "Urban und Fischer Verlag GmbH und Co. KG",

number = "2-4",

}

TY - JOUR

T1 - Targeting of anti-tumor responses with bispecific antibodies

AU - Segal, D. M.

AU - Qian, J. H.

AU - Mezzanzanica, D.

AU - Garrido, M. A.

AU - Titus, J. A.

AU - Andrew, S. M.

AU - George, A. J T

AU - Jost, C. R.

AU - Perez, P.

AU - Wunderlich, J. R.

PY - 1992

Y1 - 1992

N2 - T cells can be induced to specifically lyse tumor cells with bispecific antibodies containing anti-T cell receptor mAbs crosslinked to anti-tumor mAbs. Such targeted cytolysis requires that the target cell be bound directly to the cytotoxic cell. In addition, targeted T cells mediate a second activity, the secretion of factors that can block the growth of both tumor target cells and bystander tumor cells. When given to nude mice bearing intraperitoneal human ovarian carcinoma, targeted human T cells cause the rapid removal of most tumor cells from the peritoneum, and markedly prolong the times of survival of treated mice. The efficacy of targeted T cells for treating human cancer is currently being tested in clinical trials.

AB - T cells can be induced to specifically lyse tumor cells with bispecific antibodies containing anti-T cell receptor mAbs crosslinked to anti-tumor mAbs. Such targeted cytolysis requires that the target cell be bound directly to the cytotoxic cell. In addition, targeted T cells mediate a second activity, the secretion of factors that can block the growth of both tumor target cells and bystander tumor cells. When given to nude mice bearing intraperitoneal human ovarian carcinoma, targeted human T cells cause the rapid removal of most tumor cells from the peritoneum, and markedly prolong the times of survival of treated mice. The efficacy of targeted T cells for treating human cancer is currently being tested in clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0026781592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026781592&partnerID=8YFLogxK

M3 - Article

C2 - 1452212

AN - SCOPUS:0026781592

VL - 185

SP - 390

EP - 402

JO - Immunobiology

JF - Immunobiology

SN - 0171-2985

IS - 2-4

ER -

Targeting of anti-tumor responses with bispecific antibodies

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this